Advanced oxidation protein products. Part II. the significance of oxidation protein products in the pathomechanism of diabetes and its complications;Zaawansowane produkty utleniania białek. Czȩść II. Znaczenie w patomechanizmie cukrzycy i jej powikłaniach

Polski Merkuriusz Lekarski

Volumn 28, Issue 165, 2010, Pages 227-230

  Piwowar, Agnieszka ^a  

^a WROCLAW MEDICAL UNIVERSITY   (Poland)

Author keywords

Advanced oxidation protein products; Diabetes; Diabetic complications

Indexed keywords

ADVANCED GLYCATION END PRODUCT; MULTIENZYME COMPLEX;

ARTICLE; DIABETES MELLITUS; HUMAN; METABOLISM; OXIDATION REDUCTION REACTION; OXIDATIVE STRESS; DIABETES COMPLICATIONS;

DIABETES COMPLICATIONS; DIABETES MELLITUS; GLYCOSYLATION END PRODUCTS, ADVANCED; HUMANS; MULTIENZYME COMPLEXES; OXIDATION-REDUCTION; OXIDATIVE STRESS;

EID: 77951181216     PISSN: 14269686     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (41)

1. Ardestani A., Yazdanparast R., Jamshidi Sh.: Therapeutic effects of Teucrium polium extract on oxidative stress in pancreas of streptozotocin induced diabetic rats. J. Med. Food, 2008, 11, 525-532.
2. Atabek M.E., Keskin M., Yazici C i wsp.: Protein oxidation in obesity and insulin resistance. Eur. J. Pediatr., 2006, 165, 753-756.
3. Baskol G., Gumus K., Oner A. i wsp.: The role of advanced oxidation protein products and total thiols in diabetic retinopathy. Eur. J. Ophthalmol., 2008, 18, 792-798.
4. Boulanger E., Moranne O., Wautier M.P. i wsp.: Changes in glycation and oxidation markers in patients starting peritoneal dialysis: a pilot study. Perit Dial. Int.. 2006, 26, 207-212.
5. Cakatay U.: Protein oxidation parameters in type 2 diabetic patients with good and poor glycaemic control. Diabetes Metab., 2005, 31, 551-557.
6. Cakatay U., Kayali R., Uzun H.: Relation of plasma protein oxidation parameters and paraoxonase acticity in the ageing population. Clin. Exp. Med., 2008, 8, 51-57.
7. Capeillere-Blandin C., Gausson V., Nguyen A.T. i wsp.: Respective role of uraemic toxins and myeloperoxidase in the uraemic state. Nephrol. Dial. Transplant, 2006, 21, 1555-1563.
8. Demirbilek M.E., Kilic N., Komurcu H.F. i wsp.: Advanced oxidation protein products in aged with dementia. Am. J. Immunol., 2007, 3, 52-55.
9. Eskiocak S., Tutunculer F., Basaran U.N. i wsp.: The effect of melatonin on protein oxidation and nitric oxide in the brain tissue of hypoxic neonatal rats. Brain Dev., 2007, 29, 19-24.
10. Gallardo J.M., Prado-Uribe M.C, Amato D. i wsp.: Inflammation and oxidative stress markers by pentoxifylline treatment in rats with chronic renal failure and high sodium intake. Arch. Med. Res., 2007, 38, 34-38.
11. Gürdöl F., Cimçit M., Oner-lyidogan Y. i wsp.: Early and late effects of hyperbaric oxygen treatment on oxidative stress parameters in diabetic patients. Physiol. Res., 2008, 57, 41-47.
12. Hodkova M., Dusilova-Sulkova S., Skalicka A. i wsp.: Influence of parenteral iron therapy and oral vitamin E supplementation on neutrophil respiratory burst in chronic hemodialysis patients. Ren. Fail., 2005, 27, 135-141.
13. Kalousova M., Fialova L., Skrha J. i wsp.: Oxidative stress, inflammation and autoimmune reaction in type 1 and type 2 diabetes mellitus. Prague Med. Rep., 2004, 105, 21-28.
14. Kalousova M., Sulkova S., Fialova L. i wsp.: Glycoxidation and inflammation in chronic haemodialysis patients. Nephrol. Dial. Transplant, 2003, 18, 2577-2581.
15. Kalousova M., Zima T., Tesar V. i wsp.: Advanced glycoxidation end products in chronic diseases-clinical chemistry and genetic background. Mutat Res.. 2005, 579, 37-46.
16. Kalousova M., Zima T., Tesar V. i wsp.: Advanced glycation end products and advanced oxidation protein products in hemodialyzed patients. Blood Purif., 2002, 20, 531-536.
17. Kalousova M., Skrha J., Zima T.: Advanced glycation end-products and advanced oxidation protein products in patients with diabetes mellitus. Physiol. Res., 2002, 51, 597-604.
18. Kalusova M., Zak A., Soukupova J. i wsp.: Advanced glycation and oxidation products in patients with atherosclerosis. Cas. tek. Cesk., 2005, 144, 385-389.
19. Knapik-Kordecka M., Piwowar A., Warwas M.: Zaburzenia równowagioksydacyjno-antyoksydacyjnej a czynniki ryzyka miażdżycy i powiklania naczyniowe u chorych na cukrzycȩ typu 2. Wiad. Lek., 2007, 60, 329-334.
20. Kocak H., Oner-lyidogan Y., Gurdol E. i wsp.: Advanced oxidation protein products in obese women: it's relation to Insulin resistance and resistin. Clin. Exp. Med., 2007, 7, 173-178.
21. Kostolanska J., Jakus V., Barakt.: HbA1c and serum levels of advanced glycation and oxidation protein products in poorly and well controlled children and adolescents with type 1 diabetes mellitus. J. Pediatr. Endocrinol. Metab.. 2009. 22, 433-442.
22. Krzystek-Korpacka M., Salmonowicz B., Boehm D. i wsp.: Diagnostic potential of oxidative stress markers in children and adolescent with type 1 diabetes. Clin. Biochem., 2008, 41, 48-55.
23. Lazarova M., Stejskal D., Lacnak B. i wsp.: The antioxidant acetylocysteine reduces oxidative stress by decreasing level of AOPPs. Biomed. Papers, 2004, 148, 131-133.
24. Liu S.X., Hou F.F., Gou Z.J. i wsp.: Advanced oxidation protein products accelerate atherosclerosis through promoting oxidative stress and inflamamation. Arterioscler. Thromb. Vase. Biol., 2006, 26, 1156-1162.
25. Marsche G., Frank S., Hrzenjak A. i wsp.: Plasma-advanced oxidation protein products are potent high-density lipoprotein receptor antagonists in vivo. Circ. Res., 2009, 104, 750-757.
26. Martin-Gallan P., Carrascosa A., Gussinye M. i wsp.: Biomarkers of diabetes-associated oxidative stress and antioxidant status in young diabetic patients with or without subclinical complications. Free Radie. Biol. Med., 2003. 34, 1563-1574.
27. Meaney E., Vela A., Samaniego V. i wsp.: Metformina, arterial function, intima-media thickness and nitroxidation in metabolic syndrome: the mefisto study. Clin. Exp. Pharmacol. Physiol., 2008, 35, 895-903.
28. Pan H.Z., Zhang H., Chang D. i wsp.: The change of oxidative stress products in diabetes mellitus and diabetic retinopathy. Br. J. Ophthalmol., 2008, 92, 548-551.
29. Pan H.Z., Zhang L., Guo M.Y. i wsp.: The oxidative stress status in diabetes mellitus and diabetic nephropathy. Acta Diabetot, 2009, Published online.
30. Piwowar A., Knapik-Kordecka M., Szczednska J. i wsp.: Plasma glycooxldation protein products in type 2 diabetic patients with nephropathy. Diabetes Metab. Res. Rev., 2008, 24, 549-553.
31. Piwowar A., Knapik-Kordecka M., Warwas M.: AOPP and its relation with selected markers of oxidative/antioxidative system in type 2 diabetes mellitus. Diabetes Res. Clin. Pract., 2007, 77, 188-192.
32. Schleicher E., Friess U.: Oxidative stress, AGE, and atherosclerosis. Kidney Int. Suppl. 2007, 106. S17-S26.
33. Sebekova K., Boor P., Valachovicova M. i wsp.: Association of metabolic syndrome risk factors with selected markers of oxidative status and microinflammation in healthy omnivores and vegetarians. Mol. Nutr. Food. Res.. 2006, 50, 858-868.
34. Shi X.Y., Hou F.F., Niu H.X. i wsp.: Advanced oxidation protein products promote inflammation in diabetic kidney through activation of renal nicotinamide adenine dinucleotide phosphate oxidase. Endocrinology, 2008, 149, 1829-1839.
35. Skvarilova M., Bulva A., Stejskal D. i wsp.: Increase level of advanced oxidation protein products (AOPP) as a marker of oxidative stress in patients with acute coronary syndrome. Biomed. Papers, 2005,149, 83-87.
36. Wei X.F., Zhou Q.G., Hou F.F. i wsp.: Advanced oxidation protein products induce mesangial cet perturbation through PKC-dependent activation of NADPH oxidase. Am. J. Physiol. Renal Physiol.. 2009, 296, F427-F437.
37. Witko-Sarsat V., Friedlander M., Nguyen Khoa T. i wsp.: Advanced oxidation protein products as novel mediators of inflammation and monocyte activation in chronic renal failure. J. Immunol., 1998, 161, 2524-2532.
38. Witko-Sarsat V., Gausson V., Descamps-tatscha B.: Are advanced oxidation protein products potential uremic toxins? Kidney Int. Suppl., 2003, 84, 11-14.
39. Witko-Sarsat V., Gausson V., Nguyen AT. i wsp.: AOPP-induced activation of human neutrophil and monocyte oxidative metabolism: A potential target for N-acetylcystelne treatment in dialysis patients. Kidney InL, 2003, 64, 82-91.
40. Wu Z.X., Xue Y.M., Li C.Z. i wsp.: Advanced oxidation protein products in diabetic nephropathy patients and its relation with superoxide dismutase, glutathione peroxidase, neopterin. Zhong. Nan. Da. Xue. Xue. Bao. Yi. Xue. Ban., 2005. 30, 704-707.
41. Yang X.B., Hou F.F., Wu Q. i wsp.: Increased levels of advanced oxidation protein products are associated with atherosclerosis in chronic kidney disease. Zhonghua Nei. Ke. Za. Zhi, 2005, 44, 342-346.